Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 513

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 513
---
 Biochemistry from the University of Zürich (1988). Dr. Barberis is well qualified to serve as Director because of his extensive management and leadership experience in the biotech industry, startup companies, and in the private and public scientific research sectors. Seng Chin Mah, PhD, Independent Director Seng Chin Mah will become a Director upon Closing of the Business Combination. Dr. Mah has been Chairman of the Board of BioVersys AG since 2009. He was previously Chief Executive Officer of the Canyon Pharmaceuticals Group AG (2009 -2021) and has over 30 years’ experience in the pharma and biotech industry. Prior to Canyon Pharmaceuticals, he was Head of Development of the Integration Office during the integration of Chiron into Novartis (2005 -2008) and held other positions at Novartis, including Global Head of Clinical Safety and Epidemiology (2001 -2005); Head of Drug Regulatory Affairs Europe (1997 -2001); and oversight responsibility for Clinical Quality Assurance (2001 -2005). Dr. Mah was also a member of the Novartis Corporate Executive Group (2001 -2005) and a member of the Board of Directors for Novartis Europharm Ltd. (1997 -2005). During his tenure with Novartis and Ciba (1990 -2008), he drove key drug development and regulatory programs, and led major business results including numerous global registrations of major products. He has held several research and academia positions (Ciba -GeigyLtd., 1987 -1988; National University of Singapore, 1989 -1990). Dr. Mah was awarded The Frost & Sullivan 2011 Product Differentiation Excellence Award in Parenteral Anticoagulants, which recognized Canyon Pharmaceuticals Group AG for the development and launch of Iprivask ®(desirudin for injection). Dr. Mah earned a BS in Pharmacology from University of London (1984) and a PhD in Biochemistry from University of Basel (1987). Dr. Mah is well qualified to serve as a Director because of his extensive knowledge and experience in strategic decision -making, late -stageclinical development and regulatory experience within the Pharma and Biotech industry. Hyuk Joo Jee, Independent Director Hyuk Joo Jee will become a Director upon Closing of the Business Combination. Mr. Jee has served as a Special Advisor to Chairman at DongKoo Bio Pharma Co., Ltd., a public company in Korea, since January 202